心房顫動市場規模、佔有率及成長分析（按治療類型、最終用途和地區）－2025-2032 年產業預測

Atrial Fibrillation Market Size, Share, and Growth Analysis, By Treatment type (Pharmacological Treatment, Non-Pharmacological Treatment), By End-Use (Hospitals, Specialty Clinics), By Region - Industry Forecast 2025-2032

出版日期: 2025年03月12日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年心房顫動市場規模價值為 233.1 億美元，預計將從 2024 年的 258.5 億美元成長到 2032 年的 591.5 億美元，預測期內（2025-2032 年）的複合年成長率為 10.9%。

由於心房顫動盛行率不斷上升（尤其是在老齡化社會）以及心導管電氣燒灼術等治療技術的進步，心房顫動市場正在經歷顯著成長。目前，美國約有2%的65歲以下人群和約9%的65歲以上人群被診斷患有心房顫動，預計到2050年，美國心房顫動患者人數將迅速增加到600萬至1600萬，到2060年，歐洲心房顫動患者人數將增加到900萬至1400萬。然而，市場挑戰依然存在，包括專家短缺和治療成本上升。雷射和射頻應用等新治療方法的整合既是挑戰也是機會。此外，藥物和設備的協同效應有望改善治療效果，進而進一步擴大市場。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Johnson & Johnson（USA）
Abbott Laboratories（USA）
Medtronic plc（Ireland）
Boston Scientific Corporation（USA）
AtriCure Inc.（USA）
MicroPort Scientific Corporation（China）
Koninklijke Philips NV（Netherlands）
Biotronik SE & Co. KG（Germany）
Siemens AG（Germany）
Boehringer Ingelheim GmbH（Germany）
Sanofi-Aventis（France）
Bristol-Myers Squibb Company（USA）
CardioFocus Inc.（USA）
Biosense Webster Inc.（USA）
Endoscopic Technologies Inc.（USA）
St. Jude Medical（USA）
AliveCor, Inc.（USA）
Milestone Pharmaceuticals Inc.（Canada）

結論和建議

簡介目錄

Product Code: SQMIG35E2044

Atrial Fibrillation Market size was valued at USD 23.31 billion in 2023 and is poised to grow from USD 25.85 billion in 2024 to USD 59.15 billion by 2032, growing at a CAGR of 10.9% during the forecast period (2025-2032).

The atrial fibrillation (AFib) market is witnessing significant growth, driven by rising incidence rates, particularly among the aging population, and advancements in treatment technologies like catheter ablation. Currently, about 2% of individuals under 65 and nearly 9% of those over 65 in the U.S. are diagnosed with AFib, with projections indicating that cases could soar to between 6-16 million by 2050 in the U.S. and from 9 million to 14 million in Europe by 2060. However, market challenges, including a shortage of specialists and the high costs of treatment, persist. The integration of novel therapies, such as laser and radiofrequency applications, poses both a challenge and opportunity, as do synergies between medications and devices that could enhance management outcomes and stimulate further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Atrial Fibrillation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Atrial Fibrillation Market Segments Analysis

Global Atrial Fibrillation Market is segmented by Treatment type, End-Use and region. Based on Treatment type, the market is segmented into Pharmacological Treatment and Non-Pharmacological Treatment. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Atrial Fibrillation Market

The atrial fibrillation market is primarily driven by the increasing aging population, which is particularly susceptible to this condition. According to the World Health Organization (WHO), by 2030, roughly one in six people worldwide will be aged 60 or older, indicating a significant demographic shift. The number of individuals in this age group is projected to grow from 1 billion in 2020 to 1.4 billion in 2030, and by 2050, it is expected to reach 2.1 billion. Moreover, there will be a substantial rise in the population aged 80 and above, with estimates suggesting a threefold increase to 426 million by 2050. This demographic trend highlights the urgent need for effective treatments and management strategies for atrial fibrillation as the population ages.

Restraints in the Atrial Fibrillation Market

The substantial expenses associated with treating atrial fibrillation represent a significant obstacle to the advancement of the atrial fibrillation market. According to research from Science Direction, the average hospitalization cost per patient is approximately USD 3,530 (with a 95% confidence interval of $3,328 to $3,732), while outpatient facility visits average around USD 3,878 (with a 95% confidence interval of $3,769 to $3,987). Additionally, emergency room visits incur an average charge of $394 (with a 95% confidence interval of $358 to $430). These high treatment costs are likely to impede the growth of the atrial fibrillation market significantly.

Market Trends of the Atrial Fibrillation Market

The atrial fibrillation (AFib) market is witnessing significant growth driven by the rising prevalence of the condition, which currently affects approximately 37.57 million individuals worldwide. The National Institutes of Health reports a 33% increase in incidence over the past two decades, highlighting a concerning trend, particularly in countries with middle socio-demographic indices. Modern lifestyle factors, including obesity, hypertension, and diabetes, are exacerbating the situation, further contributing to the market's expansion. As healthcare systems adapt to manage this growing demand, the AFib market is poised for innovation, with an increase in treatment options, diagnostic tools, and patient management solutions emerging as key trends.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement

Global Atrial Fibrillation Market Size by Treatment type & CAGR (2025-2032)

Market Overview
Pharmacological Treatment
- Anti-arrhythmic Drugs
- Anticoagulant Drugs
Non-Pharmacological Treatment
- Catheter Ablation
- Radiofrequency
- HIFU
- Cryoablation
- Microwave
- Laser
- Maze Surgery
- Electric Cardioversion

Global Atrial Fibrillation Market Size by End-Use & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Others

Global Atrial Fibrillation Market Size & CAGR (2025-2032)

North America (Treatment type, End-Use)
- US
- Canada
Europe (Treatment type, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment type, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment type, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment type, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AtriCure Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MicroPort Scientific Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotronik SE & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi-Aventis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CardioFocus Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosense Webster Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endoscopic Technologies Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
St. Jude Medical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AliveCor, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Milestone Pharmaceuticals Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments